Propylthiouracil for Alcoholic Liver Disease

Bret A. Lashner, Alfred L. Baker, Daniel S. Seidman, H. Orrego, Joan E. Blake, L. M. Blendis, K. V. Compton, Y. Israel

Research output: Contribution to journalLetterpeer-review


To the Editor: The randomized clinical trial of propylthiouracil for treatment of alcoholic liver disease reported in the Journal (Dec. 3 issue)1 was well designed and well implemented. The authors concluded that propylthiouracil affects long-term mortality favorably. It is noteworthy that most of the deaths in the placebo group (11 of 20) occurred within the first 12 weeks of the study. By contrast, only 3 of the 10 deaths in the propylthiouracil group occurred during the first 12 weeks. An earlier randomized clinical trial by the same group of researchers demonstrated no short-term survival advantage with propylthiouracil therapy.2 Presumably, the.

Original languageEnglish
Pages (from-to)1471-1472
Number of pages2
JournalNew England Journal of Medicine
Issue number22
StatePublished - 2 Jun 1988
Externally publishedYes


Dive into the research topics of 'Propylthiouracil for Alcoholic Liver Disease'. Together they form a unique fingerprint.

Cite this